AR061623A1 - Derivados de acido fenilacetico - Google Patents

Derivados de acido fenilacetico

Info

Publication number
AR061623A1
AR061623A1 ARP070102780A ARP070102780A AR061623A1 AR 061623 A1 AR061623 A1 AR 061623A1 AR P070102780 A ARP070102780 A AR P070102780A AR P070102780 A ARP070102780 A AR P070102780A AR 061623 A1 AR061623 A1 AR 061623A1
Authority
AR
Argentina
Prior art keywords
acid derivatives
phenylacetic acid
alkyl
halo
pharmaceutical use
Prior art date
Application number
ARP070102780A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667003&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR061623A1 publication Critical patent/AR061623A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos que son utiles para el tratamiento de trastornos COX-2 dependientes. Reivindicacion 1: Un compuesto de formula (1) donde R es metilo o etilo; R3 es halo o alquilo C1-6; R4 es alquilo C1-6; R5 es halo; estando el alquilo C1-6 mencionado con anterioridad en R3 y R4 sustituido con uno o más grupos halo; sales aceptables para uso farmacéutico del mismo; y ésteres aceptables para uso farmacéutico del mismo.
ARP070102780A 2006-06-26 2007-06-22 Derivados de acido fenilacetico AR061623A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80578406P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
AR061623A1 true AR061623A1 (es) 2008-09-10

Family

ID=38667003

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070102780A AR061623A1 (es) 2006-06-26 2007-06-22 Derivados de acido fenilacetico
ARP170101176A AR108389A2 (es) 2006-06-26 2017-05-05 Derivados de ácido fenilacético

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101176A AR108389A2 (es) 2006-06-26 2017-05-05 Derivados de ácido fenilacético

Country Status (27)

Country Link
US (3) US8362294B2 (es)
EP (1) EP2046723B1 (es)
JP (1) JP5258761B2 (es)
KR (1) KR101380423B1 (es)
CN (1) CN101479231A (es)
AR (2) AR061623A1 (es)
AU (1) AU2007265181B2 (es)
BR (1) BRPI0713523A8 (es)
CA (1) CA2655676C (es)
CL (1) CL2007001857A1 (es)
CR (1) CR10506A (es)
EC (1) ECSP088988A (es)
ES (1) ES2386989T3 (es)
GT (1) GT200800296A (es)
IL (1) IL195958A (es)
MA (1) MA30567B1 (es)
MX (1) MX2008016337A (es)
MY (1) MY145122A (es)
NO (1) NO20090292L (es)
PE (1) PE20080213A1 (es)
PL (1) PL2046723T3 (es)
PT (1) PT2046723E (es)
RU (1) RU2454402C2 (es)
TN (1) TNSN08531A1 (es)
TW (1) TW200817309A (es)
WO (1) WO2008002853A2 (es)
ZA (1) ZA200810562B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156809B2 (en) 1999-12-17 2007-01-02 Q-Tec Systems Llc Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity
JP5841073B2 (ja) 2010-02-19 2016-01-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ３−アミノカルボニル置換ベンゾイルシクロヘキサンジオン類及び除草剤としてのそれらの使用
JP6250893B2 (ja) * 2015-02-13 2017-12-20 トヨタ自動車株式会社 ブローバイガス処理装置およびインテークマニホールド
CN105669732B (zh) * 2016-01-10 2017-05-31 沧州普瑞东方科技有限公司 一种合成4‑氟‑5‑异丙基‑2‑甲氧基苯硼酸的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133740C (es) 1965-04-08
FI49600C (fi) 1967-12-20 1975-08-11 Ciba Geigy Ag Menetelmä substituoitujen fenyylietikkahappojen ja näiden suolojen val mistamiseksi.
JPS51149252A (en) 1975-06-14 1976-12-22 Ikeda Mohandou:Kk A process for preparing naphthylaminophenyl acetic acid derivatives
US4001878A (en) 1975-11-19 1977-01-04 Rca Corporation Charge transfer color imagers
JPS5268159A (en) 1975-12-03 1977-06-06 Ikeda Mohando Co Production of naphthyl aminophenyl acetic acid derivatives
JPS5283822A (en) 1976-01-01 1977-07-13 Ikeda Mohando Co Naphthylaminopheny acetic acid derivatives and salts thereof*
JPS5770848A (en) 1980-10-20 1982-05-01 Zenyaku Kogyo Kk Preparation of o-substituted phenylacetic acid
WO1982001366A1 (en) 1980-10-20 1982-04-29 Kogyo Kk Zenyaku Process for preparing o-(2,6-dichloroanilino)phenylacetic acid
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US6355680B1 (en) 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
PT1192131E (pt) 1999-06-10 2004-11-30 Warner Lambert Co Metodo para inibicao da agergacao de proteinas amiloides e para visualizar depositos amiloides utilizando derivados de isoindolina
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
WO2003020268A1 (en) * 2001-08-31 2003-03-13 Washington University Method for the treatment and prevention of cachexia
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
KR20060125710A (ko) 2003-10-01 2006-12-06 폴리플라스틱스 가부시키가이샤 폴리아세탈 수지 조성물
EP2224472B8 (en) 2007-12-17 2014-03-19 JX Nippon Mining & Metals Corporation Substrate and method for manufacturing the same

Also Published As

Publication number Publication date
US8362294B2 (en) 2013-01-29
RU2009102271A (ru) 2010-08-10
BRPI0713523A8 (pt) 2018-05-02
ZA200810562B (en) 2009-11-25
GT200800296A (es) 2009-03-19
AR108389A2 (es) 2018-08-15
CR10506A (es) 2009-02-02
US20140058129A1 (en) 2014-02-27
AU2007265181B2 (en) 2010-11-25
TNSN08531A1 (en) 2010-04-14
US8586782B2 (en) 2013-11-19
JP2009541487A (ja) 2009-11-26
IL195958A0 (en) 2009-09-22
RU2454402C2 (ru) 2012-06-27
US20130012585A1 (en) 2013-01-10
WO2008002853A3 (en) 2008-02-07
KR20090025366A (ko) 2009-03-10
PL2046723T3 (pl) 2012-12-31
CN101479231A (zh) 2009-07-08
KR101380423B1 (ko) 2014-04-01
IL195958A (en) 2016-09-29
US20090209648A1 (en) 2009-08-20
CA2655676C (en) 2014-07-22
CA2655676A1 (en) 2008-01-03
AU2007265181A1 (en) 2008-01-03
PT2046723E (pt) 2012-09-20
ECSP088988A (es) 2009-01-30
EP2046723A2 (en) 2009-04-15
WO2008002853A2 (en) 2008-01-03
JP5258761B2 (ja) 2013-08-07
EP2046723B1 (en) 2012-07-18
BRPI0713523A2 (pt) 2012-02-14
MX2008016337A (es) 2009-01-16
PE20080213A1 (es) 2008-05-08
MY145122A (en) 2011-12-30
MA30567B1 (fr) 2009-07-01
CL2007001857A1 (es) 2008-06-13
TW200817309A (en) 2008-04-16
ES2386989T3 (es) 2012-09-10
NO20090292L (no) 2009-01-26

Similar Documents

Publication Publication Date Title
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
BRPI1014572B8 (pt) Imidazopirazinas para uso como inibidores de cinase
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
RS52605B (en) Benzoic Acids (1-Phenyl-2-pyridin-4-yl) -ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
AR082102A1 (es) Derivados de acido (2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
AR061134A1 (es) Derivados de tioxantina
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
AR053135A1 (es) Compuestos betamimeticos eficaces a largo plazo para el tratamiento de enfermedades respiratorias
AR059619A1 (es) Derivados halogenados de sulfonamidas
UY32632A (es) Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica.
UY33150A (es) Compuestos carboxamida y su uso como inhibidores v de calpaína
AR108389A2 (es) Derivados de ácido fenilacético
UY32246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
BR112013015604A2 (pt) novo derivado de isoquinolina substituído
MX339727B (es) Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para estabilizar el compuesto.
UA111103C2 (uk) Ароматичні фосфатні естери як компонент агрохімічного складу
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos

Legal Events

Date Code Title Description
FG Grant, registration